Approximately 90% of the later stage pancreatic cancers are found to be K-ras mutated and seem to get "addicted" to K-ras overactivity (induced by K-ras mutation), which might in turn have implications for therapeutically targeting the K-ras pathway [4,5]. Here, KRAS is linked to pancreatic neoplasm.